Bipolar Disorders in Saudi Arabia: What Do We Know So Far?

被引：0

作者：

Almadani, Ahmad H. ^{[1
,2
]}

Alhadi, Ahmad N. ^{[1
,2
,3
]}

Aldawood, Buthainah D. ^{[4
]}

Aleissa, Mariam M. ^{[5
,6
]}

Alosaimi, Fahad D. ^{[1
,2
]}

机构：

[1] King Saud Univ, Coll Med, Dept Psychiat, Riyadh, Saudi Arabia

[2] King Saud Univ, King Saud Univ Med City, Dept Psychiat, Riyadh, Saudi Arabia

[3] King Saud Univ, Coll Med, SABIC Psychol Hlth Res & Applicat Chair, Riyadh, Saudi Arabia

[4] Princess Nourah bint Abdulrahman Univ, Coll Hlth & Rehabil Sci, Dept Clin Psychol, Riyadh, Saudi Arabia

[5] Publ Hlth Lab, Dept Mol Genet, Publ Hlth Author, Riyadh, Saudi Arabia

[6] Alfaisal Univ, Med Sch, Riyadh, Saudi Arabia

来源：

SAUDI JOURNAL OF MEDICINE & MEDICAL SCIENCES | 2025年 / 13卷 / 01期

关键词：

Bipolar disorders; clinical manifestations; epidemiology; etiology; psychotropic medications; Saudi Arabia; OUTPATIENT PSYCHIATRIC SETTINGS; PREVALENCE; PATTERNS; INPATIENT; DIAGNOSES; STIGMA;

D O I：

10.4103/sjmms.sjmms_306_24

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bipolar disorders (BP) are prevalent neuropsychiatric illnesses affecting 1%-5% of the global population and about 3% of the Saudi population. They are associated with significant comorbidities and negative consequences. Despite being common mental health conditions in Saudi Arabia, stigma persists, with weak character, supernatural beliefs, and weak faith considered as causes. In addition, Saudi patients with BP have been reported to seek help from non-psychiatric healthcare professionals and faith healers. More data are required on BP from Saudi Arabia, including the genetic aspects and their treatment approaches. This narrative review paper explores the epidemiology and clinical manifestations, etiology and biological mechanisms, public knowledge and awareness of the illnesses, and treatment of BP in Saudi Arabia.

引用

页码：1 / 6

页数：6

共 50 条

[1] Clozapine for bipolar disorder: What do we know so far and what next?
Kapczinski, Flavio
Pfaffenseller, Bianca
Dursun, Serdar M.
de Azevedo Cardoso, Taiane
BIPOLAR DISORDERS, 2021, 23 (02) : 115 - 116
[2] Vitamin D and Temporomandibular Disorders: What Do We Know So Far?
Kui, Andreea
Buduru, Smaranda
Labunet, Anca
Balhuc, Silvia
Negucioiu, Marius
NUTRIENTS, 2021, 13 (04)
[3] Amyloidogenesis: What Do We Know So Far?
Alraawi, Zeina
Banerjee, Nayan
Mohanty, Srujana
Kumar, Thallapuranam Krishnaswamy Suresh
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
[4] ASPHALTENES: WHAT DO WE KNOW SO FAR
Al-Qasim, Abdulaziz S.
Alasker, Mohammed
PROCEEDINGS OF THE ASME 36TH INTERNATIONAL CONFERENCE ON OCEAN, OFFSHORE AND ARCTIC ENGINEERING, 2017, VOL 8, 2017,
[5] Trichotillomania: What Do We Know So Far?
Melo, Daniel Fernandes
Lima, Caren dos Santos
Piraccini, Bianca Maria
Tosti, Antonella
SKIN APPENDAGE DISORDERS, 2022, 8 (01) : 1 - 7
[6] Probiotics: What Do We Know So Far?
Steinberg, Skylar
Hazan, Sabine
PRACTICAL GASTROENTEROLOGY, 2018, 42 (10) : 68 - 70
[7] Crowdfunding: What Do We Know So Far?
Jovanovic, Tanja
INTERNATIONAL JOURNAL OF INNOVATION AND TECHNOLOGY MANAGEMENT, 2019, 16 (01)
[8] PEComa: what do we know so far?
Hornick, JL
Fletcher, CDM
HISTOPATHOLOGY, 2006, 48 (01) : 75 - 82
[9] Immune Disorders in Hashimoto's Thyroiditis: What Do We Know So Far?
Pyzik, Aleksandra
Grywalska, Ewelina
Matyjaszek-Matuszek, Beata
Rolinski, Jacek
JOURNAL OF IMMUNOLOGY RESEARCH, 2015, 2015
[10] Refractory hypertension: what do we know so far?
Elizabeth Silaid Muxfeldt
Bernardo Chedier
Journal of Human Hypertension, 2021, 35 : 181 - 183

← 1 2 3 4 5 →